Morningstar

SynAct Pharma's CEO and CSO Sell Shares

Provided by ACCESS Newswire

LUND, SE / ACCESS Newswire / September 3, 2026 / SynAct Pharma AB (STO:SYNACT) ("SynAct Pharma" or the "Company") today announces that the Company's Chief Executive Officer, Jeppe Øvlesen, and the Company's CSO, Thomas Jonassen, have sold shares in the Company to enable payment of capital gain tax.

Jeppe Øvlesen's sale of a total of 150,000 shares at a price of SEK 17.8 per share was carried out through the closely associated company Quantass Aps. Following the sale, Jeppe Øvlesen holds 229,422 shares and 722,688 warrants in the Company.

Thomas Jonassen's sale of a total of 350,000 shares at a price of SEK 17.8 per share was carried out through the related company TJ Biotek Aps. Following the sale, Thomas Jonassen holds 2,195,320 shares and 516,205 warrants in the Company.

The sales have been necessary for the sellers to enable their payment of capital gain tax in Denmark.

For additional information about SynAct, please contact
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

Attachments
SynAct Pharma's CEO and CSO sell shares

SOURCE: SynAct Pharma



View the original press release on ACCESS Newswire

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark

Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options.
Russel Kinnel and Ivanna Hampton

The Top Funds for a Simpler Retirement Portfolio

For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio.
Christine Benz

3 Stocks to Sell and 3 Stocks to Buy for October

Plus, lessons from September’s stock market activity.
David Sekera, CFA and Susan Dziubinski

10 Top-Performing US Dividend Stocks

Chevron and Pfizer are among Q3's high-yielding winners.
Bella Albrecht

Sponsor Center